Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

suicide prevention drug

- PMLiVE

Novartis’ Scemblix granted FDA accelerated approval in newly diagnosed CML

Approximately 9,280 new cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

Astellas’ Vyloy approved by FDA as first-line gastric cancer combination treatment

Approximately 26,890 new cases of gastric cancer will be diagnosed in the US this year

- PMLiVE

GSK’s investigational antibiotic granted FDA priority review for urinary tract infections

Gepotidacin could be the first in a new class of oral antibiotics for uncomplicated UTIs in over 20 years

- PMLiVE

Pfizer’s Hympavzi granted FDA approval to treat haemophilia in adult and paediatric patients

More than 800,000 people globally are affected by the genetic blood disorder

- PMLiVE

FDA advisory committee recommends Stealth’s elamipretide for Barth syndrome

The ultra-rare genetic disease affects approximately 150 people in the US

- PMLiVE

Roche’s Itovebi combination granted FDA approval for advanced breast cancer

Approximately 310,720 women will be diagnosed with invasive breast cancer in the US this year

- PMLiVE

Bristol Myers Squibb’s Opdivo regimen granted FDA approval in NSCLC

More than 200,000 people are diagnosed with lung cancer in the US every year

- PMLiVE

FDA approves IntraBio’s Aqneursa to treat Niemann-Pick disease type C patients

The rare lysosomal storage disorder affects approximately one in every 100,000 to 120,000 births

- PMLiVE

AstraZeneca’s Tagrisso approved by FDA to treat EGFR-mutated lung cancer

More than 200,000 people are diagnosed with lung cancer in the US every year

- PMLiVE

FDA grants rare paediatric disease designation to Enterprise’s cystic fibrosis candidate

The genetic disease is estimated to affect more than 100,000 people globally

- PMLiVE

Sanofi’s Sarclisa granted FDA approval to treat newly diagnosed multiple myeloma

Approximately 32,000 people are diagnosed with the haematological malignancy in the US every year

- PMLiVE

FDA approves Zevra’s Miplyffa as first drug for Niemann-Pick disease type C

The rare lysosomal storage disorder affects approximately 900 people in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links